Expert Opinion on Pharmacotherapy最新文献_第2页

Pharmacotherapeutic management of psoriatic disease: addressing psoriatic arthritis and cutaneous manifestations. 银屑病的药物治疗：解决银屑病关节炎和皮肤表现问题。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-21 DOI: 10.1080/14656566.2024.2419563

Robin C Yi, Hannah Y Gantz, Shailey C Shah, Shannon K Moran, Yael E Klionsky, Steven R Feldman

{"title":"Pharmacotherapeutic management of psoriatic disease: addressing psoriatic arthritis and cutaneous manifestations.","authors":"Robin C Yi, Hannah Y Gantz, Shailey C Shah, Shannon K Moran, Yael E Klionsky, Steven R Feldman","doi":"10.1080/14656566.2024.2419563","DOIUrl":"https://doi.org/10.1080/14656566.2024.2419563","url":null,"abstract":"Introduction: Psoriasis and psoriatic arthritis (PsA) are interrelated autoimmune conditions sharing similar genetic and immunological pathways. PsA often develops within 10 years of psoriasis onset, though it may precede cutaneous symptoms in some patients. Effective management of these conditions requires a multidisciplinary approach to address skin, bone, joint, and vascular manifestations.Areas covered: The review summarizes the current pharmacotherapies and to provide treatment guidelines for managing cutaneous psoriasis and PsA in psoriatic disease.Expert opinion: The management for mild psoriasis and mild PsA flare-ups can be addressed with topical treatments and with NSAIDs or intra-articular glucocorticoid injections. For more persistent or severe cases, systemic treatments with oral small molecules (Methotrexate, Apremilast, Janus kinase inhibitors) or with biologics (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, CTLA-4 Ig) are effective in managing both psoriasis and PsA. With many treatment options, providers can tailor management, which considers patient disease severity, preference, comorbidities, and other factors. Early detection and a multidisciplinary management strategy can optimize patient quality of life and improve health outcomes.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent developments in drug treatment strategies for infertility in patients with polycystic ovary syndrome. 多囊卵巢综合征患者不孕症药物治疗策略的最新进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-20 DOI: 10.1080/14656566.2024.2418985

Stefano Palomba, Marianna Molinaro, Alice Ingargiola, Antonio Aversa

{"title":"Recent developments in drug treatment strategies for infertility in patients with polycystic ovary syndrome.","authors":"Stefano Palomba, Marianna Molinaro, Alice Ingargiola, Antonio Aversa","doi":"10.1080/14656566.2024.2418985","DOIUrl":"10.1080/14656566.2024.2418985","url":null,"abstract":"Introduction: Infertility related to polycystic ovary syndrome (PCOS) represents a significant challenge for women of reproductive age. Over the last few years, evidence-based medicine has driven new approaches for treating infertility in patients with PCOS, changing rapidly and deeply the clinical practice.Areas covered: The authors provide an in-depth examination of recent developments in drug treatment strategies that have impacted the clinical practice and changed the previous approach to infertility in patients with PCOS.Expert opinion: The authors identify four primary areas of interest that have impacted clinical practice in the last few years. Specifically, they discuss the current role of metformin administration in women with PCOS and infertility, the choice for using clomiphene citrate or letrozole as first-line treatment for ovulation induction, the use of new gonadotropin formulations for in vitro fertilization (IVF) program, and the elective embryo transfer in IVF cycles as golden standard treatment for patients with PCOS at high-risk for ovarian hyperstimulation syndrome.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on the pharmacological management of acne vulgaris: the state of the art. 药物治疗寻常痤疮的最新进展：最新技术。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-20 DOI: 10.1080/14656566.2024.2418986

Isabel Cristina Valente Duarte de Sousa

{"title":"An update on the pharmacological management of acne vulgaris: the state of the art.","authors":"Isabel Cristina Valente Duarte de Sousa","doi":"10.1080/14656566.2024.2418986","DOIUrl":"https://doi.org/10.1080/14656566.2024.2418986","url":null,"abstract":"Introduction: Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit that affects approximately 9.4% of the global population. Current treatment strategies aim to target as many pathogenic factors involved in the appearance of acne lesions and are centered on a systematic treatment escalation based on disease severity, extension, and treatment response, starting with topical treatments for mild cases and progressing over to systemic therapies in more severe cases. A literature search, which included clinical guidelines, clinical studies, and review articles on acne treatment and maintenance, was conducted to review the pharmacological approaches currently available to treat this disease.Areas covered: Topical therapies such as topical retinoids, benzoyl peroxide, azelaic acid, salicylic acid, topical antibiotics, and clascoterone, as well as systemic treatments such as oral antibiotics and isotretinoin are discussed in detail. Combined oral contraceptives and spironolactone will not be discussed in this article.Expert opinion: There is a need for a blockbuster acne drug that simultaneously targets the four main pathogenic factors involved in the appearance of acne lesions while presenting with minimal side effects. Until such a drug exists, combination therapy will remain the standard of treatment for most acne patients.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment. 研究尼罗加司他对需要系统治疗的进展期类脂膜瘤成人患者的疗效。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-18 DOI: 10.1080/14656566.2024.2418416

Fernando Campos, Bernd Kasper

{"title":"Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment.","authors":"Fernando Campos, Bernd Kasper","doi":"10.1080/14656566.2024.2418416","DOIUrl":"https://doi.org/10.1080/14656566.2024.2418416","url":null,"abstract":"Introduction: Desmoid tumor (DT) is a rare, locally aggressive, mesenchymal neoplasm that can arise at any site in the body. Medical therapies play a major role for DT's patients requiring treatment. A novel systemic approach has recently emerged with Nirogacestat, a γ-secretase inhibitor targeting the NOTCH signaling pathway.Areas covered: Nirogacestat is the first drug in its class to receive approval from the Food and Drug Administration (FDA) and is the first FDA-approved treatment specifically for DTs. We reviewed the data leading to its discovery, including its mechanism of action, pharmacological properties, clinical efficacy, and its positioning within the current treatment armamentarium for DTs.Expert opinion: High-quality evidence for systemic therapies in the management of DTs remains an unmet need. Nirogacestat now joins sorafenib as the only drugs with efficacy in DTs demonstrated by randomized phase 3 studies. Currently, there are no comparative trials of the available systemic therapies. Therefore, physicians should consider factors such as drug accessibility, cost, toxicity profile, comorbidities, and patient preferences when selecting treatment. Long-term efficacy and safety data will be essential for evaluating the duration of treatment response and monitoring late-onset side effects of Nirogacestat.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria. 治疗阵发性夜间血红蛋白尿的色甘平。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-15 DOI: 10.1080/14656566.2024.2404110

Carlos M de Castro, Bhumika J Patel

{"title":"Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.","authors":"Carlos M de Castro, Bhumika J Patel","doi":"10.1080/14656566.2024.2404110","DOIUrl":"https://doi.org/10.1080/14656566.2024.2404110","url":null,"abstract":"Introduction: Standard-of-care first-line treatments for paroxysmal nocturnal hemoglobinuria (PNH) include the anti-C5 therapies eculizumab and ravulizumab. However, persistent anemia, likely due to extravascular hemolysis, and reduced quality of life (QoL) due to frequent infusions remain concerns. Iptacopan is a first-in-class oral proximal complement inhibitor that targets factor B in the alternative pathway (upstream of C5), limiting intravascular and extravascular hemolysis.Areas covered: In patients previously treated with anti-C5 therapies or naive to complement inhibitors, iptacopan 200 mg twice daily resulted in clinically meaningful results in the pivotal phase 3 APPLY-PNH (NCT04558918) and APPOINT-PNH (NCT04820530) trials. Treatment with iptacopan was safe, and no treatment-related adverse events led to discontinuation.Expert opinion: APPLY-PNH and APPOINT-PNH reported clinically meaningful improvements in hemoglobin, bilirubin, and lactate dehydrogenase levels; transfusion avoidance; reticulocyte count; and fatigue. Iptacopan's safety profile was comparable to other complement inhibitors. Oral iptacopan therapy allows patients to avoid infusions, limit clinical visits, decrease medical costs, improve anemia that persists with other complement inhibitors, and improve QoL. Long-term follow-up will further assess infections, thrombosis, and breakthrough hemolysis. Before treatment, physicians need to discuss current therapeutic options with patients for shared decision-making. Guidelines are being created to assist healthcare professionals in this advancing field.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric pharmacotherapy: a challenge with complex roots. 儿科药物治疗：根源复杂的挑战。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-13 DOI: 10.1080/14656566.2024.2415700

Klaus Rose

引用次数: 0

The first five years of SARS-CoV-2: inpatient treatment updates and future directions. SARS-CoV-2最初的五年：住院治疗的最新进展和未来方向。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-09-24 DOI: 10.1080/14656566.2024.2408375

Matthew W McCarthy

引用次数: 0

GLP-1 receptor agonists: new kids in the block of renoprotection for people with type 2 diabetes and chronic kidney disease. GLP-1 受体激动剂：为 2 型糖尿病和慢性肾病患者提供肾脏保护的新生力量。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-10-13 DOI: 10.1080/14656566.2024.2416584

Theocharis Koufakis, Djordje S Popovic, Paschalis Karakasis, Panagiotis Georgianos, Dimitrios Patoulias

引用次数: 0

The pharmacological management of alcohol-related cirrhosis: what's new? 酒精相关肝硬化的药物治疗：有什么新进展？

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-10-03 DOI: 10.1080/14656566.2024.2409941

Nipun Verma, Ashwin P Vinod, Ashwani K Singal

{"title":"The pharmacological management of alcohol-related cirrhosis: what's new?","authors":"Nipun Verma, Ashwin P Vinod, Ashwani K Singal","doi":"10.1080/14656566.2024.2409941","DOIUrl":"10.1080/14656566.2024.2409941","url":null,"abstract":"Introduction: Alcohol use disorder (AUD) is present in the majority of patients with alcohol-associated liver disease (ALD), which leads to about 50% of cirrhosis-related hospitalizations and over 25% of deaths worldwide. Patients with ALD often present at an advanced stage, like cirrhosis with its complications and alcohol-associated hepatitis (AH), which has high short-term mortality. Current treatments are limited, with the limited benefit of glucocorticoids only in the short-term among patients with AH, highlighting an urgent need for novel therapies.Areas covered: This review applies the PIRO (Predisposition, Injury, Response, Organ dysfunction) concept to ALD, understanding an ongoing process of liver damage, and opportunities to address and halt the progression. We also highlight the significance of treating AUD to improve long-term outcomes in ALD.Expert opinion: Personalized therapies targeting specific genetic profiles and multiple pathogenic pathways are crucial in managing ALD. Emerging therapies like gut-liver-brain axis modulators like fecal microbiota transplant and probiotics, interleukin-22, granulocyte-colony stimulating factor (G-CSF) and stem cells, epigenetic regulators of inflammation and regeneration are encouraging with the potential of efficacy in patients with ALD. Liver transplantation (LT) is a definitive therapy for advanced cirrhosis with increasing impetus on early LT select patients with active alcohol use.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacotherapy of persistent genital arousal disorder/genito-pelvic dysesthesia: an updated review and data from a registry. 持续性生殖器唤起障碍/生殖器盆腔感觉障碍的药物治疗：最新回顾和登记数据。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-10-23 DOI: 10.1080/14656566.2024.2415696

Tillmann H C Kruger, Sophie Köhne, Franziska M L M Kümpers

{"title":"Pharmacotherapy of persistent genital arousal disorder/genito-pelvic dysesthesia: an updated review and data from a registry.","authors":"Tillmann H C Kruger, Sophie Köhne, Franziska M L M Kümpers","doi":"10.1080/14656566.2024.2415696","DOIUrl":"10.1080/14656566.2024.2415696","url":null,"abstract":"Introduction: Persistent genital arousal disorder/genitopelvic dysesthesia (PGAD/GPD) is a rare, yet debilitating disease, which has been included in ICD-11. Pharmacotherapy in PGAD/GPD is a mixed blessing - drugs may either alleviate symptoms or worsen/induce them. Therefore, we aim at offering both an overview of pharmacological approaches to treat this disorder, including treatment failures, and to highlight drugs that may induce or worsen symptoms. We include all available data published so far as well as data from an own registry.Areas covered: The international registries have not recorded any completed or ongoing trials on pharmacotherapy of PGAD/GPD. We refer to case reports, case series, online surveys, and data from our own registry that includes 90 subjects with PGAD/GPD.Expert opinion: There is weak evidence (level 4) that some drugs such as SSRIs, SNRIs, cannabinoids, and anticonvulsants (pregabalin and gapabentin) may alleviate symptoms in PGAD/GPD. However, serotonergic drugs may also induce or worsen PGAD/GPD during administration or termination, as observed in 28% of cases. In conclusion, the pharmacotherapy of PGAD/GPD is still in its infancy just like the etiopathological understanding of the disease. Clinicians should be aware of PGAD/GPD, conduct careful diagnostics, and discuss an individual treatment plan with the patient.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0